![Weekly Enforcement Update: Inflated Claims Are a Key Theme](https://www.g2intelligence.com/wp-content/uploads/2023/02/Feb15-2023.News_.WeeklyEnforcement-CarePlans-iStock-1404067941_1800x1250-1080x675.jpg)
Weekly Enforcement Update: Inflated Claims Are a Key Theme
Though last week’s cases didn’t involve labs or lab testing, most were FCA-related issues including inflated claims.
Though last week’s cases didn’t involve labs or lab testing, most were FCA-related issues including inflated claims.
Specially crafted lab tests speed up adoption of novel drug treatments.
Q4 2022 financial results released by three key lab companies over the past week mainly included losses, but there were positives as well.
Influential panel cites lack of evidence of tests’ harms and benefits.
Agency says it will continue to have authority to clear new lab tests and other COVID-19 products on an emergency basis even after the PHE ends.
As we move further into 2023, COVID-19, add-on, and genetic tests will likely remain targets for federal regulators.
Get up to date on annual billing changes and critical developments currently facing laboratory medicine.
A new OIG Advisory Opinion sheds some light on how to properly structure these arrangements in a hospital inpatient setting.
Recent fraud case involving phlebotomy company shows why labs need to pay special attention to Medicare specimen collection and travel allowance rules.
A look at the US end-of-emergency game plan and how it will impact lab compliance.